Hesse Eric, Moessinger Eckart, Rosenthal Herbert, Laenger Florian, Brabant Georg, Petrich Thorsten, Gratz Klaus F, Bastian Leonard
Department of Trauma Surgery, Hannover Medical School, Germany.
J Bone Miner Res. 2007 Jan;22(1):158-62. doi: 10.1359/jbmr.060909.
In oncogenic osteomalacia, the causative tumor is almost always difficult to find. A novel diagnostic approach is presented that facilitates a precise and rapid localization of the associated lesion by PET-CT co-registration using the radiotracer (68)Ga-DOTANOC.
Oncogenic osteomalacia (OOM) is an uncommon disorder characterized by hyperphosphaturia, hypophosphatemia, decreased vitamin D(3) serum levels, and osteomalacia. The paraneoplastic syndrome is exclusively driven by a small somatostatin receptor (sst)-positive tumor that produces phosphatonins, proteins that cause renal phosphate loss. OOM can be cured completely on tumor removal. However, the exact tumor localization is the most challenging step, because the lesion is notoriously difficult to detect by common imaging techniques.
A 60-year-old woman complained of severe pain in her back and chest wall, muscle weakness, and reduced physical activity for >1 year. She suffered a metatarsal fracture and presented with hyperphosphaturia and hypophosphatemia. OOM was suspected, and a meticulous search for the tumor was initiated by conventional imaging techniques, sst-mediated imaging using (111)In-octreotide scintigraphy, and (68)Ga-DOTANOC-based positron emission tomography (PET)-CT co-registration. (68)Ga-DOTANOC is a novel radiopharmaceutical compound in which the somatostatin analog octreotide is modified at position 3, chelated with DOTA, and complexed with (68)Gallium. (68)Ga-DOTANOC has an improved affinity to sst2 and sst5 relative to other radiopeptides.
Whereas common imaging techniques such as CT failed to localize the tumor, (111)In-octreotide scintigraphy was able to detect the lesion, but only PET-CT using (68)Ga-DOTANOC revealed the exact tumor localization in the right femoral head. On tumor resection, the well being of the patient improved significantly, and biochemical parameters returned to normal.
(68)Ga-DOTANOC-based PET-CT is a novel and powerful approach to detect sst-positive tumors in a timely manner and to provide highly resolved images facilitating the development of a therapeutic strategy.
在肿瘤性骨软化症中,致病肿瘤几乎总是难以找到。本文介绍了一种新的诊断方法,该方法通过使用放射性示踪剂(68)Ga-DOTANOC进行PET-CT配准,有助于精确快速地定位相关病变。
肿瘤性骨软化症(OOM)是一种罕见的疾病,其特征为高磷尿症、低磷血症、血清维生素D3水平降低和骨软化症。这种副肿瘤综合征完全由一种小的生长抑素受体(sst)阳性肿瘤驱动,该肿瘤产生磷调节素,即导致肾脏磷流失的蛋白质。切除肿瘤后,OOM可完全治愈。然而,准确的肿瘤定位是最具挑战性的步骤,因为通过常规成像技术很难检测到该病变。
一名60岁女性主诉背部和胸壁剧痛、肌肉无力且身体活动减少超过1年。她发生了跖骨骨折,并出现高磷尿症和低磷血症。怀疑为OOM,通过传统成像技术、使用(111)In-奥曲肽闪烁扫描的sst介导成像以及基于(68)Ga-DOTANOC的正电子发射断层扫描(PET)-CT配准对肿瘤进行了细致的查找。(68)Ga-DOTANOC是一种新型放射性药物化合物,其中生长抑素类似物奥曲肽在3位进行了修饰,与DOTA螯合,并与(68)镓络合。相对于其他放射性肽,(68)Ga-DOTANOC对sst2和sst5具有更高的亲和力。
虽然CT等常规成像技术未能定位肿瘤,但(111)In-奥曲肽闪烁扫描能够检测到病变,但只有使用(68)Ga-DOTANOC的PET-CT揭示了肿瘤在右股骨头的确切位置。肿瘤切除后,患者的健康状况显著改善,生化指标恢复正常。
基于(68)Ga-DOTANOC的PET-CT是一种新颖且强大的方法,能够及时检测sst阳性肿瘤,并提供高分辨率图像,有助于制定治疗策略。